ESMO Asia 2023 | Next steps in utilizing DCE-MRI to predict MK-2206 response in breast cancer

Jiang Zhang, PhD, The Hong Kong Polytechnic University, Hong Kong, China, outlines next steps following the use of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to identify biomarkers in patients with early-stage, high-risk breast cancer, to predict their response to the Akt inhibitor MK-2206. To assess whether prediction accuracies can be further improved, biomarker changes should be monitored over the course of treatment; this could have applications in clinical settings, helping doctors decide whether treatment should continue or be changed. To further understand the underlying mechanism of this treatment, research should be conducted to investigate how biomarker change is associated with the genomic environment. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.